PROM1 and cancer: To validate the clinical relevance of CD133 to human cancers and its contribution to maintenance of the CSC population in tumors, we used immunohistochemical (IHC) staining and scoring analysis [16, 17] to assess CD133 in sections of human lung (35 primary and 10 metastatic) and breast (56 primary and 79 metastatic) cancer.